Influenza, Human, Pneumonia, Pneumococcal, Covid19
Conditions
Interventions
Experimental group:1st dose: combined vaccination of COVIV+IIV4
2nd dose: combined vaccination of COVIV+PPV23
Control group A:1st dose: COVIV only
Control group B:1st dose: IIV4 only
2nd dose: PPV23 only
Sponsors
Shanghai Municipal Center for Disease Control and Prevention
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years old when enrolled; 2. Participants signing the informed consent; 3. Being able to participate in all planned follow-ups and accomplish all research procedures including completing a diary card and coming back for interview; 4. Having not been administered any pneumonia vaccine or COVID-19 vaccine, and having not been administered an influenza vaccine in the current season before enrollment; 5. >=14 days from the most recent vaccination; 6. Before enrollment, the body temperature <=37.0 degree C as confirmed by medical history and clinical examination.
Exclusion criteria
Exclusion criteria: 1. Having a history of COVID-19 or a positive nucleic acid test for COVID-19; 2. Having a history or a family history of allergy, convulsion, epilepsy, brain disease, or mental illness; 3. Being allergic to any component of vaccines, or having a history of severe allergic reaction to any vaccine; 4. Having immunodeficiency disorder, during treatment of malignant tumor, having immunodeficiency induced by immunosuppressants (oral steroid hormones) or HIV, or having a family member with close contact who suffers from congenital immune disorder; 5. Having injection of non-specific immunoglobulin within 1 month prior to enrollment; 6. Having acute febrile illness or communicable disease; 7. Having a history of confirmed thrombocytopenia or other coagulation disorders, which may cause contraindications for a subcutaneous injection; 8. Having severe chronic disease or acute exacerbation of chronic disease, or having uncontrolled hypertension or diabetes; 9. Having various infectious, pyogenic, or allergic skin diseases; 10. Women in pregnancy or lactation or participants who plan for a baby within 3 months after vaccination should delay the vaccination; 11. Having any condition that may affect trial assessment as determined by researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seroconversion rate;Antibody positive rate ;Neutralizing antibody level; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reaction; | — |
Countries
China
Contacts
Public ContactXiaodong Sun
Shanghai Municipal Center for Disease Control and Prevention
Outcome results
None listed